dc.contributor.author
Darbà, Josep
dc.contributor.author
Ramírez, Gabriela
dc.contributor.author
García-Rivero, Juan L.
dc.contributor.author
Mayoralas, Sagrario
dc.contributor.author
Pascual, José Francisco
dc.contributor.author
Vargas, Diego
dc.contributor.author
Bijedic, Adi
dc.date.issued
2017-03-02T15:15:56Z
dc.date.issued
2017-03-02T15:15:56Z
dc.date.issued
2017-03-02T15:15:56Z
dc.identifier
https://hdl.handle.net/2445/107750
dc.description.abstract
The objective of this study was to estimate the economic impact of the introduction of DuoResp® Spiromax®, budesonide/formoterol fixed-dose combination (FDC), focusing on an increase in medication adherence due to an enhancement of the inhalation technique for the treatment of COPD patients in Spain and 5 regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ...
dc.format
application/pdf
dc.publisher
Dove Medical Press
dc.relation
Reproducció del document publicat a: https://doi.org/10.2147/CEOR.S125301
dc.relation
Clinicoeconomics and Outcomes Research, 2017, vol. 9, num. February, p. 127-137
dc.relation
https://doi.org/10.2147/CEOR.S125301
dc.rights
cc-by-nc (c) Darbà, Josep et al., 2017
dc.rights
http://creativecommons.org/licenses/by-nc/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Economia)
dc.subject
Administració de medicaments
dc.subject
Malalties pulmonars obstructives cròniques
dc.subject
Tractament tèrmic
dc.subject
Economia de la salut
dc.subject
Administration of drugs
dc.subject
Chronic obstructive pulmonary diseases
dc.subject
Heat treatment
dc.subject
Medical economics
dc.title
Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
